OBJECTIVES: Ticagrelor reduces thrombotic events compared with clopidogrel in patients with acute coronary syndrome, but may also increase bleeding complications. Coronary artery bypass grafting (CABG)-related bleeding complications have not previously been compared in clopidogrel and ticagrelor-treated patients outside the controlled environment of clinical trials.
INTRODUCTION
Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (aspirin) and clopidogrel has been standard of care in acute coronary syndromes (ACSs) for over a decade. Clopidogrel blocks the ADP-dependent pathway to platelet aggregation irreversibly via the P2Y 12 receptor. Two new, more effective P2Y 12 inhibitors, prasugrel (Eli Lilly & Company, Indianapolis, IN, USA) and ticagrelor (AstraZeneca, London, UK), have recently been introduced into clinical practice. The new inhibitors improve outcome in ACS patients and the most recent guidelines therefore recommend the use of ASA and one of the new platelet inhibitors as first-line treatment in the majority of ACS patients [1, 2] . DAPT reduces the risk of thrombotic episodes in ACS patients but is also associated with a significantly increased risk of excessive bleeding [3] [4] [5] . The risk of bleeding complications is further enhanced with new P2Y 12 inhibitors [4] [5] [6] . Bleeding complications are strongly associated with poor outcome in ACS patients [7] , and current guidelines therefore recommend discontinuation of P2Y 12 inhibitors in elective surgical procedures while aspirin treatment is maintained [1] .
Ticagrelor is a reversible direct-acting P2Y 12 inhibitor. Ticagrelor has faster on-set and off-set and results in more potent platelet inhibition than clopidogrel [8] . Ticagrelor and clopidogrel were compared in the PLATO trial in ACS patients [4] where ticagrelor was superior in terms of a combined primary end-point (cardiovascular death, myocardial infarction and stroke) and mortality, without increasing the overall incidence of bleeding complications.
However, in a more detailed analysis, spontaneous and noncoronary artery bypass grafting (CABG) bleeding complications were more common in ticagrelor-treated patients [6] , which could be expected given the more potent platelet inhibition. CABGrelated bleeding complications have not previously been compared between clopidogrel-and ticagrelor-treated patients outside the PLATO trial.
In this study, we wanted to determine the prevalence of major CABG-related bleeding complications in patients with ACS treated with ticagrelor or clopidogrel in a 'real-life' setting.
METHODS

Patients
Four hundred and five ACS patients (mean age 67 ± 10 years, 19% women) who were accepted for acute or urgent CABG at Sahlgrenska University Hospital from January 2012 to June 2013 were prospectively included in a single-centre observational study. During this time, ticagrelor was being introduced in western Sweden to replace clopidogrel as the first treatment option in ACS patients planned for interventional treatment. The patients were admitted from the hospital's own catchment area or referred from the surrounding hospitals in western Sweden, and were treated with aspirin and ticagrelor (n = 173) or aspirin and clopidogrel (n = 232). The study was not randomized; instead, consecutive patients with the respective treatment were included and groups were formed depending on which P2Y 12 inhibitor was used before surgery. Analysis groups were also formed based on time from discontinuation of P2Y 12 inhibitors to time of surgery, giving three groups: (i) medication discontinued according to guidelines (5 days or more); (ii) medication discontinued 2-4 days before surgery and (iii) medication discontinued 0-1 day before surgery. Aspirin was not discontinued before surgery. Fondaparinux (GlaxoSmithKline, Brentford, UK) and low-molecular-weight heparin was discontinued at least 12 h before elective surgery. Patient characteristics are shown in Table 1 . The study was approved by the Regional Research Ethics Committee who waived the need for individual consent from the patients included.
Study design
The groups were compared regarding intraoperative and postoperative bleeding parameters and transfusion requirements. Primary end-point was major bleeding complications modified from the definition in the blood conservation using antifibrinolytics in a randomized trial (BART) study [9] , including one or more of the following criteria: postoperative blood loss >1500 ml/12 h, re-exploration due to bleeding, red blood cell (RBC) transfusion of 10 units or more or death because of bleeding. Secondary end-points were reoperation due to bleeding, postoperative bleeding volume (defined as the total amount of chest tube drainage during the first 12 h after surgery), total bleeding volume (intraoperative bleeding and chest tube drainage 12 h after surgery), number of transfusions of packed RBCs, plasma and platelets; percentage of patients transfused with RBCs, plasma and platelets; and 30-day mortality. Thrombolysis in myocardial infarction (TIMI) CABG-related bleeding was defined as bleeding resulting in death, reoperation due to bleeding, intracranial haemorrhage, transfusion of five or more units of RBCs over 48 h or chest tube drainage in excess of 2000 ml over 24 h [10] . Since these latter data were unavailable because the majority of the chest tubes were withdrawn after 14-18 h, chest tube drainage over 24 h was approximated by deriving an extrapolation factor from 20 patients with chest tube drainage over 24 h and multiplying it by the chest tube drainage after 12 h. This approximation was only used to calculate the prevalence of TIMI CABG-related bleeding. Otherwise, the chest tube drainage after 12 h is presented. PLATO life-threatening major bleeding was defined as fatal bleeding, pericardial bleeding requiring repeat surgery, drop in haemoglobin of ≥5.0 g/dl or transfusion of four or more units of RBCs [4] . PLATO major bleeding was defined as pericardial bleeding requiring repeat surgery, drop in haemoglobin of ≥3.0 g/dl or transfusion of two or more units of RBCs [4] . Data were obtained from hospital charts and the hospital's surgical database.
Clinical management
All patients were operated with cardiopulmonary bypass (CPB). Before cannulation, heparin (Lövens, Ballerup, Denmark), 300 IU/ kg, was given and supplemented as required to maintain an activated clotting time of more than 480 s. The standard uncoated extracorporeal circuit was primed with approximately 1700 ml of Ringer's acetate (Fresenius-Kabi, Uppsala, Sweden), 200 ml of mannitol (Fresenius-Kabi), 100 ml of Tribonate (Fresenius-Kabi), and 7500 IU of heparin. CPB was performed with a hollow-fibre membrane oxygenator. All patients received 2-g tranexamic acid before surgery and 2 g after skin closure. Aprotinin was not used.
The operations were performed with standard non-pulsatile CPB technique with mild hypothermia (35-36°C) and haemodilution (haematocrit 20-30%). A standard flow of 2.4 l/min/m 2 was used. Cardioprotection was achieved with cold blood cardioplegia. Weaning off CPB was performed after rewarming to a rectal temperature of at least 36°C. Protamine (1 mg protamine/100 units of heparin) was given to reverse the effect of heparin. Cell saver was not used routinely. Transfusion of RBCs during CPB was administered at haematocrit below 20%. Postoperatively, RBCs were considered at haemoglobin levels of <7 g/dl or <10 g/dl with symptoms of anaemia. Plasma and platelets were considered with bleeding in excess of 200 ml/h and documented dysfunction of coagulation factors and/or platelets from thromboelastography.
Statistics
Data are presented as mean and standard deviation, median with range or frequencies and percentages. Continuous variables were compared using Mann-Whitney U-test for both normally distributed values (due to inequality in group size) and also for comparing distribution across groups of data that were not normally distributed. Normality of data was tested with the Kolmogorov-Smirnov test. Categorical variables were compared with Fisher's exact test. For statistical analysis, SPSS Statistics 20 (IBM Corp., Armonk, NY, USA) was used. Statistical significance was assumed with two-sided P-values of <0.05.
RESULTS
General
When all patients were compared, the primary end-point of major bleeding complications in ticagrelor-treated and clopidogreltreated patients was not significantly different (14.5 vs 13.8%, P = 0.89). Major bleeding according to TIMI and PLATO definitions were also comparable between groups (Table 2) . Likewise, there were no significant differences for the secondary end-points percentage of patients with bleeding of >1500 ml/12 h, reoperation for bleeding, RBC transfusion ≥10 units, postoperative bleeding volume, transfusion of RBCs, plasma and platelets, or 30-day mortality between the groups (Table 2) . Mean time from discontinuation of the P2Y 12 inhibitor to surgery was significantly shorter in the ticagrelor group than in the clopidogrel group. The prevalence of major bleeding complications was significantly higher when clopidogrel or ticagrelor was discontinued 0-1 day before surgery as opposed to according to guidelines, and, for ticagrelor, there was also a significant difference between discontinuation 0-1 day before surgery vs 2-4 days before surgery (P = 0.012) (Fig. 1) .
Discontinuation according to guidelines
When either drug was discontinued ≥5 days before CABG (n = 280), there was no significant difference in major bleeding complications between ticagrelor-treated patients (n = 118) and clopidogrel-treated ADULT CARDIAC patients (n = 162) (6.8 vs 9.9%, P = 0.40). Likewise, there was no significant increase in prevalence of bleeding >1500 ml/12 h, transfusions, or rate of reoperation due to bleeding in patients treated with ticagrelor rather than clopidogrel (Table 3) .
Discontinuation 2-4 days before surgery
In the group in which CABG was performed 2-4 days from discontinuation (n = 40), there was a trend of a difference in major bleeding between ticagrelor patients (n = 16) and clopidogrel patients (n = 24), 6.3 vs 25%, but the difference did not reach statistical significance (P = 0.21). If instead the PLATO definition of lifethreatening bleeding or the TIMI-CABG definition of major bleeding were used, there were significantly more bleeding complications in the clopidogrel group (Table 3) . There was also a significantly higher number of transfusions of plasma (P = 0.014) and platelets (P = 0.015) in the clopidogrel group than in the ticagrelor group, and a trend of more transfusions of RBCs (P = 0.055). Postoperative drain loss volumes also tended to be higher in the clopidogrel group (Table 3) .
Discontinuation 0-1 day before surgery
When ticagrelor (n = 39) or clopidogrel (n = 46) was discontinued 0-1 day before surgery, there was a strong trend of a higher incidence of major bleeding complications in ticagrelor-treated patients (41 vs 22%, P = 0.063). When the PLATO definition of lifethreatening bleeding was used, the difference reached statistical significance (Table 3) . Furthermore, there tended to be more reoperations due to bleeding and more transfusions of RBCs, plasma and platelets in the group treated with ticagrelor. Rate of reoperation due to bleeding was almost doubled in the ticagrelor group compared with the clopidogrel group (11 vs 23%), but the difference did not reach statistical significance (P = 0.15) ( Table 3) .
Factors related to blood conservation using antifibrinolytics in a randomized trial major bleeding
Female sex, acute surgery, higher EuroSCORE, discontinuation of clopidogrel/ticagrelor late before surgery, preoperative serum creatinine and Canadian Cardiovascular Society class IV angina were preoperative factors associated with major bleeding complications ( Table 4) . None of these factors were significantly different between patients treated with ticagrelor and those treated with clopidogrel. Thirty-day mortality was significantly higher in patients with major bleeding complications (14 vs 2%, P < 0.001).
DISCUSSION
The main finding in this real-life study was that there was no overall difference in the prevalence of major CABG-related bleeding complications in ACS patients treated with ticagrelor and in those treated with clopidogrel. After the PLATO study, ticagrelor was introduced in clinical guidelines and given higher priority than clopidogrel in the majority of ACS patients [1, 2] . Regional guidelines in western Sweden have recommended ticagrelor since April 2012 for ACS patients intended for interventional treatment. However, the new recommendation did not have an immediate effect, and since the introduction both ACS patients treated with clopidogrel and ACS patients treated with ticagrelor have been referred to our institution for CABG. This scenario was expected, and we used the situation to perform this prospective observational study.
Better outcome with ticagrelor than with clopidogrel and comparable bleeding complications were reported from the PLATO CABG sub-study [11] . However, in that study a high incidence of major bleeding complications was reported (approximately 80% in both groups), which depended mainly on the definition of major bleeding. PLATO and TIMI definitions of major bleeding were used in that study, which includes drop in haemoglobin and moderate transfusion limits, making them unsuitable for studies in cardiac surgery populations. In the present study, we therefore chose to use the BART-study definition of major bleeding as a primary end-point, with one minor modification. In the original definition, one of the variables was postoperative chest tube drainage >1500 ml over any 8-h period during the first 24 h. Instead, we used blood loss >1500 ml over 12 h, since these data were available in our database. This blood loss is approximately three times higher than expected (Table 2) .
Using the modified BART definition, we found an overall incidence of major bleeding complications of 14.5% in the ticagrelor group and 13.8% in the clopidogrel group (P = 0.89). A post hoc analysis showed that over 15 000 patients would have to be included to demonstrate that this difference is statistically significant. When approximating PLATO and TIMI definitions of major bleeding, the results from our study are comparable with data reported in the study by Held et al. The lack of inter-group difference in overall bleeding complications thus confirms for the first time the CABG-related bleeding results from the PLATO trial, i.e. there is also no significant difference between ticagrelor and clopidogrel when using a relevant bleeding definition in a real-life population.
In the clinical guidelines, it is recommended that clopidogrel and ticagrelor be discontinued 5 days before elective surgery [1, 2] . However, DAPT cannot be discontinued in all ACS patients in need of CABG due to symptoms and/or the extension and severity of the coronary artery disease. In addition, logistical issues may have an influence. This is illustrated in the present study where approximately one-third of the patients were operated less than 5 days after discontinuation (Table 1) . It is evident from our results that bleeding complications were markedly more common in patients maintained on DAPT until 0-1 day before CABG than in patients where clopidogrel and ticagrelor were discontinued 5 days before surgery. The results indicate that this withdrawal of the P2Y 12 inhibitor before surgery is of certain importance in ticagrelor-treated patients where the prevalence of major bleeding complications was substantial (41%) when ticagrelor was discontinued 0-1 day before surgery, but significantly lower when discontinued 2-4 or 5 or more days before surgery (Fig. 1) . These results are in accordance with the results of the PLATO study, with a tendency of more bleeding with ticagrelor than with clopidogrel, even though in the PLATO set-up, clopidogrel was discontinued 5 days before surgery whereas ticagrelor was discontinued 48-72 h before surgery.
Interestingly, the results from the subgroup of patients where ticagrelor was withdrawn 2-4 days before surgery indicate that the prevalence of complications was at the same level as when ticagrelor was discontinued 5 days before surgery. This finding is also supported by the significant difference between clopidogrel and ticagrelor when using the PLATO definition of life-threatening major bleeding, with more bleeding complications in clopidogreltreated patients discontinued 2-4 days before surgery and more bleeding complications in ticagrelor-treated patients when discontinued 0-1 day before surgery (Table 3 ). This suggests that if it is not possible to wait 5 days before the operation, 2-4 days is markedly better for ticagrelor-treated patients than operating with discontinuation 0-1 day before surgery. In contrast, in patients treated with clopidogrel, the incidence of bleeding complications in patients operated 2-4 days after withdrawal was more similar to that in patients with discontinuation 0-1 day before surgery than that in patients with discontinuation 5 days before surgery. It is important to note that the group with discontinuation 2-4 days before surgery was small (n = 40), and any conclusions should be drawn with some caution. A post hoc power analysis showed that a study with 1060 patients would be necessary to show a significant difference in major bleeding complications 2-4 days after surgery, assuming that 10% have their medication withdrawn 2-4 days before surgery, as in the present study. Furthermore, the trend of differences in bleeding complications depending on time since discontinuation is coherent with the stronger platelet inhibition, lack of non-responders and the shorter off-set time of ticagrelor compared with clopidogrel [4, 8] .
The study had important limitations. Besides the inherent ones in an observational study, including selection bias, one limitation was the restricted number of patients available for inclusion, which made the analysis of secondary end-points and sub-group analyses uncertain. However, we found it important to report our experience since no real-life data have been presented previously. Another limitation of the study was that the treatment and time since discontinuation were known by the treating physicians, which may have influenced their decision to prescribe transfusions of blood products. This effect should at least in part be counteracted by the transfusion algorithms and coagulation analyses currently used at our centre, to aid in determining the need for transfusion of platelets or coagulation factors. As shown in a recent ex vivo study from our group, there is also some evidence that platelet transfusion may be less effective in patients treated with ticagrelor than in those treated with clopidogrel [12] , making it even more important to tailor transfusion therapy to the individual patient.
To summarize, the incidence of major bleeding complications did not differ between ticagrelor-or clopidogrel-treated ACS patients overall or when the platelet inhibitors were used in accordance with current guidelines in this real-life setting. In patients maintained on DAPT up to the day before surgery or longer, a strong tendency to have more bleeding complications was observed in ticagrelor-treated patients.
